Exploring the Role of Oral JAK Inhibitors in Atopic Dermatitis - Episode 9

Addressing Treatment Response and Switching Among Systemic Therapies in Atopic Dermatitis

Published on: April 18, 2025

Linda Stein Gold, MD, Lisa Swanson, MD, PhD, James Song, MD, Christopher G. Bunick, MD, PhD

Experts discuss how data from studies like JADE EXTEND, Heads Up Extension, and LEVEL UP, showing improved outcomes with JAK inhibitors in patients who failed biologic therapy, influence their clinical practice and decision-making when considering switching systemic therapies for patients with atopic dermatitis.

EP. 1: The Role of the JAK/STAT Signaling Pathway in Atopic Dermatitis

EP. 2: JAK1 Selective Inhibition and the Impact of Selectivity on Efficacy and Safety

EP. 3: Long-Term Efficacy and Safety of JAK Inhibitors in Atopic Dermatitis

EP. 4: Understanding the Origins of the Boxed Warning for JAK Inhibitors

EP. 5: Communicating With Patients on the Safety of JAK Inhibitors in Atopic Dermatitis

EP. 6: Laboratory Monitoring Plans for Oral JAK Inhibitors

EP. 7: Oral JAK Inhibitors’ Place in Atopic Dermatitis Guidelines

EP. 8: Utilizing Patient Factors to Guide Treatment Selection in Atopic Dermatitis

Now Viewing

EP. 9: Addressing Treatment Response and Switching Among Systemic Therapies in Atopic Dermatitis

EP. 10: Oral JAK Inhibitor Dose Escalation in Atopic Dermatitis Treatment

EP. 11: Key Takeaways on the Role of Oral JAK Inhibitors in Atopic Dermatitis Management

Video content above is prompted by the following:

Several studies have shown that patients who have not responded to biologic therapy can achieve improved results when switching to a JAK inhibitor. How do these data impact your clinical practice and your threshold for switching systemic therapies for patients?
JADE EXTEND
Heads Up Extension; LEVEL UP